
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc has demonstrated robust growth, with approximately 48% global FFR-CT volume expansion contributing to a notable revenue increase of $46.3 million in 3Q25, representing a year-over-year growth of around 41%. The company's gross margins improved to 76.8%, a positive increase of 90 basis points compared to the previous year, underscoring strong operational efficiency. Furthermore, continued adoption of coronary CT angiography, the expansion of new accounts, and increasing utilization metrics indicate a solid foundation for sustained growth in HeartFlow's core business.
Bears say
HeartFlow Inc has faced substantial net losses totaling $95.7 million in FY23 and $96.4 million in FY24, projecting continued financial difficulties as the company moves towards 2025, with guidance indicating revenues will remain flat. The reliance on the adoption of clinical guidelines by healthcare providers poses a significant risk to the company's business model, as widespread acceptance of the HeartFlow Platform may not be realized. Additionally, reimbursement uncertainties from third-party payors could further hinder adoption and impact the company's financial condition negatively, creating a challenging outlook for profitability.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares